An Investigation into the In Vitro Targeted Killing of CD44-Expressing Triple-Negative Breast Cancer Cells Using Recombinant Photoimmunotherapeutics Compared to Auristatin-F-Based Antibody-Drug Conjugates
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Neelakshi Mungra und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Infectious Disease and Molecular Medicine, Medical Biotechnology and Immunotherapy Research Unit, University of Cape Town, Cape Town 770…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Hyaluronan Receptors, Immunoconjugates, Aminobenzoates. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 103 Literaturangaben. Gefördert von: National Research Foundation, Department of Science and Innovation, South Africa, South African Medical Research Council.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is the deadliest form of breast cancer with limited treatment options. The persistence of highly tumorigenic CD44-expressing subpopulation referred to as cancer stem cells (CSCs), endowed with the self-renewal capacity, has been associated with therapeutic resistance, hence clinical relapses. To mitigate these undesired events, targeted immunotherapies using antibody-photoconjugate (APC) or antibody-drug conjugate (ADC), were developed to specifically release cytotoxic payloads within targeted cells overexpressing cognate antigen receptors. Therefore, an αCD44(scFv)-SNAP-tag antibody fusion protein was engineered through genetic fusion of a single-chain antibody fragment (scFv) to a SNAPf-tag fusion protein, capable of self-conjugating with benzylguanine-modified light-sensitive near-infrared (NIR) phthalocyanine dye IRDye700DX (BG-IR700) or the small molecule toxin auristatin-F (BG-AURIF). Binding of the αCD44(scFv)-SNAPf-IR700 photoimmunoconjugate to antigen-positive cells was demonstrated by confocal microscopy and flow cytometry. By switching to NIR irradiation, CD44-expressing TNBC was selectively killed through induced phototoxic activities. Likewise, the αCD44(scFv)-SNAPf-AURIF immunoconjugate was able to selectively accumulate within targeted cells and significantly reduced cell viability through antimitotic activities at nano- to micromolar drug concentrations. This study provides an in vitro proof-of-concept for a future strategy to selectively destroy light-accessible superficial CD44-expressing TNBC tumors and their metastatic lesions which are inaccessible to therapeutic light.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Infectious Disease and Molecular Medicine, Medical Biotechnology and Immunotherapy Research Unit, University of Cape Town, Cape Town 7700, South Africa.
- Centre for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington 98101, United States.
- College of Science, Department of Biotechnology, Northeastern University, Boston, Massachusetts 02115, United States.
- Department of Chemistry, University of Cape Town, PD Hahn Building, Cape Town 7700, South Africa.
- Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7700, South Africa.
- Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town 7700, South Africa.
ORCID-Profile: Fleury A Nsole Biteghe, Allan M Huysamen, Roger Hunter, Stefan Barth
Förderung
- National Research Foundation
- Department of Science and Innovation, South Africa
- South African Medical Research Council
Zitieren
APA
Mungra, N., Nsole Biteghe, F. A., Huysamen, A. M., Hardcastle, N. S., Bunjun, R., Naran, K., Lang, D., Richter, W., Hunter, R., & Barth, S. (2024). An Investigation into the In Vitro Targeted Killing of CD44-Expressing Triple-Negative Breast Cancer Cells Using Recombinant Photoimmunotherapeutics Compared to Auristatin-F-Based Antibody-Drug Conjugates. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00449
Vancouver
Mungra N, Nsole Biteghe FA, Huysamen AM, Hardcastle NS, Bunjun R, Naran K, et al. An Investigation into the In Vitro Targeted Killing of CD44-Expressing Triple-Negative Breast Cancer Cells Using Recombinant Photoimmunotherapeutics Compared to Auristatin-F-Based Antibody-Drug Conjugates. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00449
BibTeX
@article{Mungra2024,
author = {Mungra, Neelakshi and Nsole Biteghe, Fleury A and Huysamen, Allan M and Hardcastle, Natasha S and Bunjun, Rubina and Naran, Krupa and Lang, Dirk and Richter, Wolfgang and Hunter, Roger and Barth, Stefan},
title = {An Investigation into the In Vitro Targeted Killing of CD44-Expressing Triple-Negative Breast Cancer Cells Using Recombinant Photoimmunotherapeutics Compared to Auristatin-F-Based Antibody-Drug Conjugates},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00449}
}
EUVIMED